Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit Therapeutics’ mission is to resolve serious, unmet medical needs for the betterment of overall human health. Summit’s leadership is committed to making a significant positive difference in the quality and potential duration of life for oncology patients facing difficult diagnoses. Summit has enacted the path to providing patient, physician, caregiver, and societal-friendly therapies while creating opportunities for durable growth as a company by initiating two Phase III trials with its lead candidate, ivonescimab. Ivonescimab, known as SMT112 in Summit’s license territories, the United States, Canada, Europe, Japan, Latin America, including Mexico and all countries in Central America, South America, and the Caribbean, the Middle East, and Africa, and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.

Ivonescimab displays cooperative binding with each of its intended targets with higher affinity when in the presence of both PD-1 and VEGF. Ivonescimab was discovered by Akeso, Inc. (HKEX Code: 9926.HK). Ivonescimab is currently engaged in two Phase III clinical trials in Summit’s license territories, in addition to multiple Phase III clinical trials focused in China led by Akeso. Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC). Ivonescimab is an investigational therapy that is not approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).

Summit intends to expand the opportunity and potential of ivonescimab into additional solid tumors in the future, based on promising data being generated by our partners at Akeso in China, as well as potential investigator sponsored trials. Globally over 1,800+ have been treated with ivonescimab across all clinical trials to date, commencing in 2023 in Summit’s two Phase III clinical trials. Summit will continue to invest in our business and pipeline, driven by Team Summit’s unmatched capabilities, including our speed and operational excellence with the goal of bringing our mission into a reality.